Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Return on Sales (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Return on Sales for 4 consecutive years, with 24.19% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales fell 856.0% to 24.19% in Q3 2025 year-over-year; TTM through Sep 2025 was 26.65%, a 501.0% decrease, with the full-year FY2024 number at 23.1%, down 584.0% from a year prior.
  • Return on Sales was 24.19% for Q3 2025 at Orchestra BioMed Holdings, down from 23.16% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.7% in Q3 2022 to a low of 63.85% in Q4 2024.
  • A 4-year average of 21.96% and a median of 20.51% in 2024 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -3873bps in 2023, then skyrocketed 1685bps in 2024.
  • Orchestra BioMed Holdings' Return on Sales stood at 8.91% in 2022, then plummeted by -435bps to 47.64% in 2023, then plummeted by -34bps to 63.85% in 2024, then skyrocketed by 62bps to 24.19% in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Return on Sales are 24.19% (Q3 2025), 23.16% (Q2 2025), and 21.61% (Q1 2025).